Thirty-nine (51%) patients received anti-EGFR-based therapy (16 patients panitumumab and 23 irinotecan plus cetuximab), 37 (49%) patients received R or T. Among patients with L-sided tumor, 30 (53%) were treated with anti-EGFR-based therapy and 27 (47%) with R/T. The gene discussed is EGFR; the disease is neoplasm.